HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    

Zacks Mutual Fund Rank
Did you know that Zacks now ranks mutual funds? We've reinvented the way mutual funds are rated.   Try it now.
Quote:
Login Free Membership
Search:

 
Analyst Blog  

BioDelivery Awaits Final FDA Word

June 15, 2009 | Comments: 0
Recommended this article (1)
Print    Share

This morning, BioDelivery Sciences International (BDSI - Snapshot Report) announced that it has reached an agreement with the U.S. Food and Drug Administration's (FDA) Division of Anesthesia, Analgesia and Rheumatology Product on all aspects of the company's New Drug Application (NDA) on Onsolis.

The agreement includes the Risk Evaluation and Mitigation Strategy (REMS), which was the previous hurdle to approval and the key reason for the complete response letter received in August 2008. BDSI refilled the NDA in December 2008 with the updated REMS requirement.

We expect final FDA action in the next few weeks. Coming to an agreement with the reviewing division and the review team on all aspects of the NDA, including the REMS, clearly bodes well for final approval of the drug.

Approval will be a transformational event for BDSI. Not only will it bring about a $30 million milestone payment from worldwide commercialization partner, Meda AB, but BDSI will also receive double-digit royalties (we estimate 20%) on sales of Onsolis upon launch.

The breakthrough cancer pain market is highly competitive, and there are several formulations of fentanyl already on the market, with several more in late-stage development, but we believe that BDSI's BEMA technology offers significant advantages over existing delivery technologies and could allow for Onsolis to be at least a $250 million peak sales drug.

The company plans to host a conference call at 11AM EST today (June 15, 2009) to discuss the NDA status of Onsolis.

Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Free Stock Analysis From Zacks
  Includes Zacks Long-Term Recommendation and Target Price
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
  • Free  Four Zacks #1 Rank "Strong Buy" Stocks
  • Free  Timely Market Commentary
  • Free  Wealth Management Tips
  • Free  Profitable Strategy Screens
  • Free  Bull and Bear Stocks of the Day
Zacks FREE Registration

More Zacks Resources

Market Summary Feb 10, 2010 05:04 am ET
DJIA 10058.64  150.25 1.52%
NASD 2150.87  0.00 0.00%
S&P 500 1070.52  13.78 1.30%